Riskpilot← Back to searchSign inGet full accessEXACT THERAPEUTICS AS
ASActiveOrg 998317487Østre Aker Vei 19, 0581 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 201213 employees
Revenue 2024
NOK 0
EBITDA margin
—
-9% vs 2023
Equity ratio
85.0%
Financial strength
Net profit 2024
NOK -51,6M
-7% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -51M | -9% |
| Net profit | NOK -51,6M | -7% |
| Total assets | NOK 151,2M | +160% |
| Equity | NOK 128,4M | +204% |
| Employees | 13 | — |
Legal name
EXACT THERAPEUTICS AS
Org number
998317487
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
30. april 2012
Share capital
NOK 446 176
Employees
13 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Company purpose
Legemiddelutvikling og andre tjenester og produkter som naturlig faller sammen med dette, herunder å delta i andre selskaper med lignende virksomhet, kjøp og salg av aksjer, eller på annen måte gjøre seg interessert i andre foretagender samt kjøp, salg og utleie av fast eiendom.
Address
Østre Aker Vei 19, 0581 Oslo
Phone
+4747261042
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 202 | 4 070 | 5 761 | 5 207 | 5 084 | 7 860 | 5 580 | 7 428 | 0 | 52 | 55 | 4 | 0 |
| Staff expenses | −139 | −3 366 | −3 340 | −1 694 | −3 628 | −3 835 | −5 704 | −7 363 | −0 | −0 | −9 110 | −22 306 | −23 053 |
| EBITDA | −5 | −1 047 | −852 | 696 | −1 156 | −4 810 | −7 499 | −15 695 | −34 061 | −59 242 | −40 438 | −46 757 | −50 987 |
| Depreciation & amort. | −2 | −106 | −172 | −180 | −131 | −143 | −125 | −284 | −745 | −1 268 | −1 302 | −1 164 | −1 229 |
| EBIT | −7 | −1 153 | −1 024 | 516 | −1 287 | −4 953 | −7 625 | −15 980 | −34 806 | −60 510 | −41 741 | −47 920 | −52 216 |
| Net financials | −0 | −9 | 10 | −5 | 1 | 40 | 39 | 998 | 1 630 | 672 | 317 | −156 | 591 |
| Profit before tax | −7 | −1 162 | −1 014 | 511 | −1 286 | −4 914 | −7 586 | −14 982 | −33 176 | −59 838 | −41 423 | −48 076 | −51 625 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −7 | −1 162 | −1 014 | 511 | −1 286 | −4 914 | −7 586 | −14 982 | −33 176 | −59 838 | −41 423 | −48 076 | −51 625 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 338 | 2 634 | 3 292 | 4 030 | 6 823 | 20 024 | 63 232 | 51 762 | 170 390 | 115 617 | 78 421 | 58 112 | 151 194 |
| Equity | 11 | −1 151 | −2 165 | −1 654 | 760 | 8 346 | 57 061 | 42 079 | 159 478 | 104 290 | 62 543 | 42 262 | 128 439 |
| Long-term debt | 0 | 0 | 4 643 | 4 299 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 326 | 3 785 | 814 | 1 384 | 6 063 | 11 678 | 6 171 | 9 683 | 10 912 | 11 327 | 15 878 | 15 850 | 22 755 |
| Total debt | 326 | 3 785 | 5 457 | 5 684 | 6 063 | 11 678 | 6 171 | 9 683 | 10 912 | 11 327 | 15 878 | 15 850 | 22 755 |
EBITDA margin
-5098706400.0%
This company
15.8%
Market median
-32270293771% vs market
20122024
Equity ratio
85.0%
This company
38.2%
Market median
+123% vs market
20122024
Return on equity
-40.2%
This company
18.4%
Market median
-318% vs market
20122024
Net profit margin
-5162498100.0%
This company
8.1%
Market median
-63734544544% vs market
20122024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20122024
Debt / equity
0.18×
This company
0.62×
Market median
+71% vs market
20122024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PE Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
RH Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
DM Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Chairman | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2024 | — | — | |
| Deputy Chairman | 2025 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2025 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Ubs Financial Services Inc. | Company | 26.3% | 26.3% | 2024 |
Canica As | Company | 6.8% | 6.8% | 2024 |
Investinor Direkte As | Company | 6.1% | 6.1% | 2024 |
Kvåle As | Company | 4.8% | 4.8% | 2024 |
Brekke Holding As | Company | 4.7% | 4.7% | 2024 |
Paacs Invest As | Company | 4.3% | 4.3% | 2024 |
Helene Sundt As | Company | 4.3% | 4.3% | 2024 |
Verdipapirfondet Nordea Avkastning | Company | 3.9% | 3.9% | 2023 |
Caceis Bank | Company | 3.6% | 3.6% | 2024 |
| Individual | 3.4% | 3.4% | 2024 | |
| Individual | 2.9% | 2.9% | 2024 | |
Optimuspistor As | Company | 2.8% | 2.8% | 2024 |
Goldman Sachs & Co. Llc | Company | 2.0% | 2.0% | 2024 |
J.P. Morgan Se | Company | 2.0% | 2.0% | 2024 |
Kvantia As | Company | 1.8% | 1.8% | 2024 |
Dnb Bank Asa | Company | 1.6% | 1.6% | 2024 |
T.D. Veen As | Company | 1.6% | 1.6% | 2024 |
Cgs Holding As | Company | 1.4% | 1.4% | 2024 |
Norda Asa | Company | 1.4% | 1.4% | 2024 |
P53 Invest As | Company | 1.1% | 1.1% | 2024 |
Verdipapirfondet Danske Invest Norge Vekst | Company | 1.1% | 1.1% | 2024 |
Blueberry Capital As | Company | 1.1% | 1.1% | 2024 |
| Individual | 1.0% | 1.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of EXACT THERAPEUTICS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Edvard Walday | Chief Executive Officer | 0 companies |
| Rafiq Hasan | Chief Executive Officer | 0 companies |
| Dominic Michael Moreland | Chief Executive Officer | 0 companies |
| William Martin Castell | Deputy Chairman | 0 companies |
| Susanne Stuffers | Board of Directors | 0 companies |
| Jean Michael Yves Sylvain Cossery | Board of Directors | 0 companies |
| Leiv Askvig | Board of Directors | 0 companies |
| Jonathan Leslie Allis | Deputy Chairman | 0 companies |
| Hans Henrik Klouman | Board of Directors | 0 companies |
| Aitana Peire Morais | Board of Directors | 0 companies |
| Ann-Tove Kongsnes | Board of Directors | 0 companies |
| Masha Paule Nathalie Legris Strømme | Board of Directors | 0 companies |
| Anders Wold | Chairman | 0 companies |
| Flavien Daloz | Board of Directors | 0 companies |
| Jean Claude Gaston Provost | Board of Directors | 0 companies |